アトピー性皮膚炎の世界市場レポート 2025年

アトピー性皮膚炎の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.0％で174億5,000万米ドルに成長します。予測期間の成長は、生物学的療法の進歩、免疫調節薬と低分子薬、小児に特化した治療、遺伝子治療と精密医療、デジタルヘルス統合に起因すると考えられます。予測期間中の主な動向としては、外用薬の技術的進歩、小児医療への注力、環境・アレルゲン管理、精密診断ツールなどが挙げられます。

アトピー性皮膚炎の有病率の上昇は、アトピー性皮膚炎市場の大きな成長を促進すると予想されます。湿疹としても知られるアトピー性皮膚炎は、乾燥とかゆみを特徴とする皮膚疾患です。この症状に罹患する人の数が増えるにつれて、効果的な診断と治療オプションに対する需要も増加しています。例えば、英国の出版社オックスフォード・アカデミックによると、アトピー性皮膚炎は世界的に非常に普及しており、世界人口の約2.6％、2024年には約2億400万人に影響を与えるといいます。この人口には、約1億100万人の大人と1億300万人の子供が含まれます。その結果、アトピー性皮膚炎の罹患率の増加がアトピー性皮膚炎市場の拡大に拍車をかけています。

個別化医療に対する需要の高まりは、アトピー性皮膚炎市場の拡大に大きく貢献すると予測されています。個別化医療とは、薬物療法を含む医療介入を、遺伝学や分子因子などの個々の患者の特性に合わせて調整することです。このアプローチにより、副作用を最小限に抑えながら、より的を絞った効果的な治療が可能になります。例えば、2022年10月現在、75,000を超える遺伝子検査製品と300を超える個別化医薬品が報告されており、個別化された治療オプションに対する需要の急増を裏付けています。この動向は、より正確で患者中心の治療アプローチを重視することで、アトピー性皮膚炎市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のアトピー性皮膚炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のアトピー性皮膚炎市場：成長率分析
• 世界のアトピー性皮膚炎市場の実績：規模と成長, 2019-2024
• 世界のアトピー性皮膚炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界のアトピー性皮膚炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアトピー性皮膚炎市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• エモリエント剤/保湿剤
• IL-4およびPDE4阻害剤
• カルシニューリン阻害剤
• 抗生物質
• その他の薬物クラス
• 世界のアトピー性皮膚炎市場：投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外用
• 注射
• 経口
• 世界のアトピー性皮膚炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のアトピー性皮膚炎市場：コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外用コルチコステロイド
• 全身コルチコステロイド
• 世界のアトピー性皮膚炎市場：エモリエント剤または保湿剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリームとローション
• 軟膏とバーム
• バリア修復クリーム
• 世界のアトピー性皮膚炎市場：IL-4およびPDE4阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デュピルマブ（IL-4阻害剤）
• アプレミラスト（PDE4阻害剤）
• 世界のアトピー性皮膚炎市場：カルシニューリン阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タクロリムス軟膏
• ピメクロリムスクリーム
• 世界のアトピー性皮膚炎市場：抗生物質のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外用抗生物質
• 全身抗生物質
• 世界のアトピー性皮膚炎市場、その他の薬物クラスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ヒスタミン薬
• 生物学的製剤
• JAK阻害剤

第7章 地域別・国別分析

• 世界のアトピー性皮膚炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアトピー性皮膚炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アトピー性皮膚炎市場：競合情勢
• アトピー性皮膚炎市場：企業プロファイル
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Meda AB Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Astellas Pharma Inc.
• Arcutis Biotherapeutics Inc.
• Asana Biosciences LLC
• Dermavant Sciences Inc.
• Eli Lilly and Company
• Galderma SA
• Incyte Corporation
• Bayer AG
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline PLC
• F Hoffmann-La Roche AG
• LEO Pharma A/S
• Teva Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アトピー性皮膚炎市場2029：新たな機会を提供する国
• アトピー性皮膚炎市場2029：新たな機会を提供するセグメント
• アトピー性皮膚炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Atopic dermatitis is a chronic dermatological condition characterized by skin dryness and itching. This condition progresses over time and is not contagious through contact.

The main drug classes used to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory drugs that mimic cortisol and are employed in the treatment of various diseases, including rheumatological conditions, rheumatoid arthritis, lupus, and atopic dermatitis. These drugs can be administered through various modes, such as topical, injectable, and oral, and are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atopic dermatitis market size has grown rapidly in recent years. It will grow from $8.61 billion in 2024 to $9.96 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, treatment options evolution, research and development.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $17.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to biologic therapies advancements, immunomodulators and small molecule drugs, pediatric-specific treatments, gene therapy and precision medicine, digital health integration. Major trends in the forecast period include technological advancements in topicals, pediatric ad care focus, environmental and allergen management, precision diagnosis tools.

The rising prevalence of atopic dermatitis is expected to drive significant growth in the atopic dermatitis market. Also known as eczema, atopic dermatitis is a skin condition characterized by dryness and itchiness. As the number of individuals affected by this condition increases, so does the demand for effective diagnosis and treatment options. For example, according to Oxford Academic, a UK-based publishing company, atopic dermatitis is highly prevalent worldwide, impacting around 2.6% of the global population, which translates to approximately 204 million people in 2024. This population includes about 101 million adults and 103 million children. Consequently, the growing incidence of atopic dermatitis is fueling the expansion of the atopic dermatitis market.

The growing demand for personalized medicine is anticipated to contribute significantly to the expansion of the atopic dermatitis market. Personalized medicine involves tailoring medical interventions, including drug therapies, to suit individual patient characteristics, such as genetics and molecular factors. This approach ensures more targeted and effective treatments while minimizing adverse effects. For example, as of October 2022, reports indicated a vast array of over 75,000 genetic testing products and 300 personalized medicines, underlining the surging demand for tailored therapeutic options. This trend is fueling the growth of the atopic dermatitis market by emphasizing more precise and patient-centric treatment approaches.

Innovations in product development are emerging as a pivotal trend within the atopic dermatitis market, with major companies introducing novel solutions to reinforce their market position. Notably, in June 2022, Regeneron Pharmaceuticals Inc., a prominent US-based biotechnology company, secured FDA approval for Dupixent (dupilumab). Dupixent is a medication designed for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. This groundbreaking drug works by inhibiting the signaling of two critical Type 2 inflammatory sources (IL-4 and IL-13), contributing to the development of various conditions such as eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma. The approval of Dupixent represents a significant advancement in pediatric atopic dermatitis treatment, promising more effective therapeutic options for young patients.

Major companies within the atopic dermatitis market are strategically pursuing product approvals to stimulate revenue growth within their industry. Product approvals signify the official endorsement granted by health regulatory bodies, affirming the safety and effectiveness of pharmaceuticals or treatments for managing inflammatory skin conditions like atopic dermatitis. Notably, in January 2022, AbbVie Inc., a prominent US-based pharmaceutical company, secured FDA approval for Rinvoq. Rinvoq, containing upadacitinib as its active component, belongs to the class of janus kinase (JAK) inhibitors, a targeted synthetic disease-modifying antirheumatic drug. This medication received approval for treating moderate-to-severe atopic dermatitis in both adults and children aged 12 years and above. Rinvoq serves as an alternative when other treatments, including biologic medicines or conventional medications, have been ineffective in managing the condition, or when their usage is not recommended. It is noteworthy that Rinvoq (upadacitinib) can be administered in conjunction with methotrexate or as monotherapy, thereby broadening treatment options for atopic dermatitis patients.

In September 2022, Arcutis Biotherapeutics, a prominent commercial-stage biopharmaceuticals firm headquartered in the United States, finalized the acquisition of Ducentis BioTherapeutics for an undisclosed sum. This strategic acquisition is envisioned to reinforce Arcutis Biotherapeutics' position within the medical dermatology sector while enhancing its capacity to address the unmet medical needs of patients dealing with dermatological conditions. Notably, Ducentis BioTherapeutics, a preclinical-stage biotechnology company also based in the US, specializes in the development of primary treatments targeting atopic dermatitis, aligning with Arcutis Biotherapeutics' commitment to advancing therapies for this skin disorder.

Major companies operating in the atopic dermatitis market are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

North America was the largest region in the atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atopic Dermatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atopic dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atopic dermatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Corticosteroids; Emollients Or Moisturizers; IL-4 And PDE4 Inhibitors; Calcineurin Inhibitors; Antibiotics; Other Drug Classes
• 2) By Mode of Administration: Topical; Injectable; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Corticosteroids: Topical Corticosteroids; Systemic Corticosteroids
• 2) By Emollients Or Moisturizers: Creams and Lotions; Ointments and Balms; Barrier Repair Creams
• 3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor); Apremilast (PDE4 Inhibitor)
• 4) By Calcineurin Inhibitors: Tacrolimus Ointment; Pimecrolimus Cream
• 5) By Antibiotics: Topical Antibiotics; Systemic Antibiotics
• 6) By Other Drug Classes: Antihistamines; Biologics; JAK Inhibitors
• Companies Mentioned: Sanofi SA; Meda AB; Regeneron Pharmaceuticals Inc.; Novartis International AG; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atopic Dermatitis Market Characteristics

3. Atopic Dermatitis Market Trends And Strategies

4. Atopic Dermatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Atopic Dermatitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Atopic Dermatitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Atopic Dermatitis Market Growth Rate Analysis
• 5.4. Global Atopic Dermatitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Atopic Dermatitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Atopic Dermatitis Total Addressable Market (TAM)

6. Atopic Dermatitis Market Segmentation

• 6.1. Global Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Emollients/Moisturizers
• IL-4 and PDE4 Inhibitors
• Calcineurin Inhibitors
• Antibiotics
• Other Drug Classes
• 6.2. Global Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical
• Injectable
• Oral
• 6.3. Global Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Atopic Dermatitis Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Systemic Corticosteroids
• 6.5. Global Atopic Dermatitis Market, Sub-Segmentation Of Emollients Or Moisturizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creams and Lotions
• Ointments and Balms
• Barrier Repair Creams
• 6.6. Global Atopic Dermatitis Market, Sub-Segmentation Of IL-4 And PDE4 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dupilumab (IL-4 Inhibitor)
• Apremilast (PDE4 Inhibitor)
• 6.7. Global Atopic Dermatitis Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tacrolimus Ointment
• Pimecrolimus Cream
• 6.8. Global Atopic Dermatitis Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antibiotics
• Systemic Antibiotics
• 6.9. Global Atopic Dermatitis Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamines
• Biologics
• JAK Inhibitors

7. Atopic Dermatitis Market Regional And Country Analysis

• 7.1. Global Atopic Dermatitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Atopic Dermatitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Atopic Dermatitis Market

• 8.1. Asia-Pacific Atopic Dermatitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Atopic Dermatitis Market

• 9.1. China Atopic Dermatitis Market Overview
• 9.2. China Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Atopic Dermatitis Market

• 10.1. India Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Atopic Dermatitis Market

• 11.1. Japan Atopic Dermatitis Market Overview
• 11.2. Japan Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Atopic Dermatitis Market

• 12.1. Australia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Atopic Dermatitis Market

• 13.1. Indonesia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Atopic Dermatitis Market

• 14.1. South Korea Atopic Dermatitis Market Overview
• 14.2. South Korea Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Atopic Dermatitis Market

• 15.1. Western Europe Atopic Dermatitis Market Overview
• 15.2. Western Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Atopic Dermatitis Market

• 16.1. UK Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Atopic Dermatitis Market

• 17.1. Germany Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Atopic Dermatitis Market

• 18.1. France Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Atopic Dermatitis Market

• 19.1. Italy Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Atopic Dermatitis Market

• 20.1. Spain Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Atopic Dermatitis Market

• 21.1. Eastern Europe Atopic Dermatitis Market Overview
• 21.2. Eastern Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Atopic Dermatitis Market

• 22.1. Russia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Atopic Dermatitis Market

• 23.1. North America Atopic Dermatitis Market Overview
• 23.2. North America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Atopic Dermatitis Market

• 24.1. USA Atopic Dermatitis Market Overview
• 24.2. USA Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Atopic Dermatitis Market

• 25.1. Canada Atopic Dermatitis Market Overview
• 25.2. Canada Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Atopic Dermatitis Market

• 26.1. South America Atopic Dermatitis Market Overview
• 26.2. South America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Atopic Dermatitis Market

• 27.1. Brazil Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Atopic Dermatitis Market

• 28.1. Middle East Atopic Dermatitis Market Overview
• 28.2. Middle East Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Atopic Dermatitis Market

• 29.1. Africa Atopic Dermatitis Market Overview
• 29.2. Africa Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Atopic Dermatitis Market Competitive Landscape And Company Profiles

• 30.1. Atopic Dermatitis Market Competitive Landscape
• 30.2. Atopic Dermatitis Market Company Profiles
  • 30.2.1. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Meda AB Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Atopic Dermatitis Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Astellas Pharma Inc.
• 31.3. Arcutis Biotherapeutics Inc.
• 31.4. Asana Biosciences LLC
• 31.5. Dermavant Sciences Inc.
• 31.6. Eli Lilly and Company
• 31.7. Galderma SA
• 31.8. Incyte Corporation
• 31.9. Bayer AG
• 31.10. Bausch Health Companies Inc.
• 31.11. Boehringer Ingelheim International GmbH
• 31.12. GlaxoSmithKline PLC
• 31.13. F Hoffmann-La Roche AG
• 31.14. LEO Pharma A/S
• 31.15. Teva Pharmaceutical Industries Ltd.

32. Global Atopic Dermatitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atopic Dermatitis Market

34. Recent Developments In The Atopic Dermatitis Market

35. Atopic Dermatitis Market High Potential Countries, Segments and Strategies

• 35.1 Atopic Dermatitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Atopic Dermatitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Atopic Dermatitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer